Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

Search Again »

Abstract Number: 1401 • 2018 ACR/ARHP Annual Meeting
Is There a Specific Effect of Jak-Inhibitors on Pain and Fatigue in Rheumatoid Arthritis?
Itsaso Odriozola¹, Claire-Sophie Coste¹, Thomas Barnetche^2,3, Christophe Richez^4,5, Bernard Bannwarth¹ and Thierry Schaeverbeke⁶, ¹Rheumatology, CHU de Bordeaux, Bordeaux, France, ²FHU ACRONIM, Pellegrin Hospital, Bordeaux University, Bordeaux, France, ³Rheumatology, Centre hospitalier universitaire de Bordeaux - Service de Rhumatologie, Bordeaux, France, ⁴UMR CNRS 5164 - Immunoconcept, Bordeaux, France, ⁵Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, ⁶Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France
Background/Purpose: Pain and fatigue are common symptoms for patients with rheumatoid arthritis (RA).JAK inhibitors (JAKi) already proved similar efficacy on disease activity as bDMARD (anti-TNF,…
Abstract Number: 1524 • 2018 ACR/ARHP Annual Meeting
Malignancies and Serious Infections in Randomized Controlled Trials of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Maria A. Lopez-Olivo¹, Jean Tayar², Natalia Zamora³, Gregory Pratt⁴ and Maria Suarez-Almazor⁵, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, ³Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁵Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX
Background/Purpose: Two JAK inhibitors are currently approved by different agencies worldwide for their use in patients with rheumatoid arthritis. The safety profile of these agents…
Abstract Number: 2048 • 2018 ACR/ARHP Annual Meeting
In Vitro Proof-of-Concept of Pathobiology-Guided Therapy in Immune Mediated Inflammatory Arthritis
Morten Aagaard Nielsen¹, Bent Deleuran^2,3 and Tue Wenzel Kragstrup^2,3,4, ¹Of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Randers Regional Hospital, Randers, Denmark
Background/Purpose: Immune mediated inflammatory arthritis are very heterogeneous diseases including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (SpA). The available biological and targeted synthetic…
Abstract Number: 2114 • 2018 ACR/ARHP Annual Meeting
Interferon Kappa Regulates Apoptotic Response to UVB in Control and Lupus Keratinocytes
Grace Hile¹, Mrinal Sarkar², Jianhua Liu³, Tamra J. Reed⁴, Johann Gudjonsson² and Michelle Kahlenberg⁴, ¹University of Michigan, Ann Arbor, MI, ²Dermatology, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Photosensitivity, defined as increased cutaneous erythema and inflammation after ultraviolet light (UV) exposure, is a hallmark of patients with systemic lupus erythematosus (SLE), cutaneous…
Abstract Number: 2474 • 2018 ACR/ARHP Annual Meeting
Development of a Crosswalk for FACIT-10 (Psychometric Work)
Clifton O. Bingham III¹, Susan J. Bartlett^2,3, David Cella⁴, Amy M. DeLozier⁵, Luna Sun⁵, Amanda Quebe⁵, Susan Otawa⁵ and Carol L. Gaich⁵, ¹Johns Hopkins University, Baltimore, PA, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁴Northwestern University, Chicago, IL, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Fatigue in patients with rheumatoid arthritis (RA) may be measured with the 13-item Functional Assessment of Chronic Illness Therapy-Fatigue instrument (FACIT-F). The Patient-Reported Outcomes…
Abstract Number: 418 • 2017 ACR/ARHP Annual Meeting
Exploratory Analysis to Identify Factors Associated with Risk of Structural Progression, Defined As Change from Baseline
Désirée van der Heijde¹, Patrick Durez², Georg Schett³, Esperanza Naredo⁴, Mikkel Østergaard⁵, Gabriella Meszaros⁶, Pedro Lopez-Romero⁷, Francesco de Leonardis⁶ and Roy Fleischmann⁸, ¹Leiden University Medical Center, Leiden, Netherlands, ²UCL-Saint Luc, Bruxelles, Belgium, ³Department of Internal Medicine III, Institute for Clinical Immunology,, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, ⁴Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain, ⁵Glostrup Hospital, Rigshospitalet, Glostrup, Denmark, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Europe Research Center, Eli Lilly and Company, Madrid, Spain, ⁸University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Baricitinib (BARI), an oral inhibitor of Janus kinase (JAK)1 and JAK2, is being developed for the treatment of RA. RA-BEGIN (NCT01711359) was a phase…
Abstract Number: 1453 • 2017 ACR/ARHP Annual Meeting
Impact of Biological and Targeted Synthetic Dmards on Work in Patients with Chronic Inflammatory Arthritides : A Meta Analysis of Randomized Controlled Trials and Controlled Cohorts
Charlotte Traverson¹, Amandine Tubery¹, Charlotte Hua², Françoise Barchechath-Flaisler¹, Cédric Lukas³, Bernard Combe², Jacques Morel² and Cécile Gaujoux-Viala⁴, ¹Rheumatology, Nîmes University Hospital, Nîmes, France, ²Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France
Background/Purpose: The addition of biological (b) and new targeted synthetic (ts) DMARDs agents in chronic inflammatory arthritides (CIAs) therapeutic strategies has improved the possibility of…
Abstract Number: 1584 • 2016 ACR/ARHP Annual Meeting
Bari-00074565
C. Steven Ernest II, Lisa O’Brien, David Radtke, Michael Heathman, Terence Rooney, William Macias and Xin Zhang, Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib is an oral selective inhibitor of Janus kinases 1/2 and has demonstrated dose-dependent efficacy in moderate-to-severe RA patients who were DMARD-naïve or with…
Abstract Number: 1627 • 2016 ACR/ARHP Annual Meeting
Network Meta-Analysis to Assess the Relative Efficacy of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Combination Therapy for Patients with Active Rheumatoid Arthritis Despite Conventional Dmards
Steve Peterson¹, Maud Pacou², Drifa Belhadi², Suzy Van Sanden¹, Thomas Webb¹, Rita Ganguly³, Regina Kurrasch³, Ravi Rao³, Benjamin Hsu¹, Kaiyin Fei¹, Danuta Kielar¹ and Rafael Alfonso³, ¹Janssen Research & Development, LLC, Spring House, PA, ²Amaris, Paris, France, ³GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab is a human anti-interleukin-6 cytokine monoclonal antibody evaluated for the treatment of moderate to severe active rheumatoid arthritis (RA) and other diseases. Our…
Abstract Number: 2227 • 2016 ACR/ARHP Annual Meeting
Sustained Remission and Relapse Rate after Non-Conventional DMARD Withdrawal in Patients with Rheumatoid Arthritis
Andrea Ramirez-Gomez¹, Aldo Barajas-Ochoa¹, Jose Juan Castaneda-Sanchez¹, Jose Dionisio Castillo-Ortiz¹, Jorge M. Sanchez-Gonzalez² and Cesar Ramos-Remus², ¹Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, ²Vicerrectoria Academica, Universidad Autonoma de Guadalajara, Guadalajara, Mexico
Background/Purpose: The treatment of rheumatoid arthritis (RA) has evolved continuously. The introduction of non-conventional DMARDs, which include biologic and targeted synthetic DMARDs (tsDMARDs), has been…
Abstract Number: 2555 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Conventional and Targeted Synthetic Disease-Modifying Antirheumatic Drugs As Well As Glucocorticoids: A Systematic Literature Review Informing the 2016 Update of the Eular Recommendations for the Management of Rheumatoid Arthritis
Katerina Chatzidionysiou¹, Sharzad Emamikia², Jackie L. Nam³, Sofia Ramiro⁴, Josef Smolen⁵, Désirée van der Heijde⁶, Maxime Dougados⁷, Johannes WJ Bijlsma⁸, Gerd Burmester⁹, Marieke Scholte-Voshaar¹⁰, Ronald van Vollenhoven^11,12 and Robert Landewé¹³, ¹Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Paris Descartes University, Paris, France, ⁸Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁹Charité University Hospital, Berlin, Germany, ¹⁰EULAR Standing Committee of People with Arthritis/Rheumatism in Europe, Zurich, Switzerland, ¹¹Amsterdam Rheumatology Center, Amsterdam, Netherlands, ¹²Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ¹³Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: To inform the task force for the 2016 update of the EULAR recommendations for the management of RA on the evidence regarding the efficacy…
Abstract Number: 2547 • 2015 ACR/ARHP Annual Meeting
NIP-565, a Novel JAK1-Selective Inhibitor, for the Treatment of Rheumatoid Arthritis
Yuuki Hidaka¹, Takanori Nakamura², Tadashi Igarashi², Takeshi Nanya², Shuhei Hagiwara², Kazuya Takeuchi², Tomonori Yaguchi³, Yutaka Kawakami³ and Takeshi Naito², ¹Pharmaceutical Research Department, Nissan Chemical Industries,LTD., Saitama, Japan, ²Nissan Chemical Industries,LTD., Saitama, Japan, ³Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Non-selective Janus kinase (JAK) inhibitors have shown long-term efficacy in treating rheumatoid arthritis (RA). However, clinical efficacy is limited due to concerns of dose-limiting…
Abstract Number: 1514 • 2014 ACR/ARHP Annual Meeting
An Analysis of in-Vitro Cytokine Inhibition Profiles of Tofacitinib and Other Janus Kinase Inhibitors at Clinically-Meaningful Concentrations
M.E. Dowty, T.S. Lin, L. Wang, J. Jussif, B. Juba, L. Li, E. Moy and J.-B. Telliez, Pfizer Worldwide R&D, Cambridge, MA
Background/Purpose: A number of Janus kinase (JAK) inhibitors are being actively investigated for treatment of rheumatoid arthritis (RA), including tofacitinib, baricitinib, filgotinib (GLPG0634), and decernotinib…
Abstract Number: 2653 • 2012 ACR/ARHP Annual Meeting
A Subset of up-Regulated IFN Regulated Genes in Candle Patients Decrease with Treatment with a JAK Inhibitor
Adriana Almeida de Jesus¹, Yin Liu², Gina A. Montealegre³, Adam L. Reinhardt⁴, Diane Brown⁵, Antonio Torrelo⁶, Angel V. Casano⁷, Lena Das⁸, Yongqing Chen⁹, Yan Huang⁹, Deborah Stone¹⁰, Dawn C. Chapelle², Nicole Plass², Steven H. Zuckerman¹¹, William Macias¹² and Raphaela T. Goldbach-Mansky², ¹Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ²Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ³NIAMS, Bethesda, MD, ⁴Rheumatology, Children's Hosp of Omaha/UNMC, Omaha, NE, ⁵Division Of Rheumatology MS #60, Children's Hospital Los Angeles, Los Angeles, CA, ⁶Departments of Pediatric Dermatology, Hospital Niño Jesús, Madrid, Spain, Madrid, Spain, ⁷Meditex Spain, Malaga, Spain, ⁸Pediatric Rheumatology, KK Women's and Children's Hospital, Singapore, Singapore, ⁹Translational Autoinflammatory Disease Section, Office of the Clinical Director NIAMS, Bethesda, MD, ¹⁰National Institute of Arthritis & Muscoloskeletal, National Institutes of Health, Bethesda, MD, ¹¹Immunology, Lilly Research Labs, Indianapolis, IN, ¹²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome is a recently described early-onset autoinflammatory disease caused by autosomal recessive mutations in…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].